Anagenics Limited has completed a significant restructuring to simplify operations and issued 35 million shares to FOS Capital as part of this process. The company confirms its going concern status and outlines plans for organic and acquisitive growth over the next year.
Anagenics Limited reports a marked reduction in cash outflows and operating costs following a strategic restructuring, with full benefits expected in the latter half of FY2025. Despite divesting Face Medi, core cosmetics sales remain steady.